AbbVie Delivers Record $61.16 Billion in 2025 Revenues, Signals Strong Growth for 2026

Standout Immunology and Neuroscience Gains Drive Record Annual Revenues

AbbVie closed out 2025 on a strong note, posting full-year net revenues of $61.16 billion—an increase of 8.6%—highlighting the resilience and diversity of its growth platform after the U.S. loss of exclusivity for Humira. Immunology continued to anchor AbbVie’s performance, delivering $30.41 billion for the year, up 14.0%, with Skyrizi revenues alone surging nearly 50% to $17.56 billion. Neuroscience was another growth pillar, up 19.6% with products like Vraylar, Botox Therapeutic, and migraine therapies showing double-digit gains.

Fourth-Quarter Results Show Double-Digit Growth Across Core Segments

In the fourth quarter, net revenues rose to $16.62 billion, climbing 10% on a reported basis. Immunology stood out, growing 18.3%, while Skyrizi and Rinvoq posted particularly strong gains of 32.5% and 29.5%, respectively. The neuroscience portfolio expanded by 17.9%, propelled by newer launches and broadening indications. Meanwhile, oncology revenues dipped by 1.5%, dragged by declines in Imbruvica, partly offset by growth in Venclexta and new assets like Elahere and Epkinly.

Product Portfolio Overview: Strengths and Shifting Markets

Humira, once AbbVie’s main profit driver, saw U.S. sales slide following generic competition, but Skyrizi and Rinvoq more than offset these declines. The company’s aesthetics segment contracted 6.1% on the year, mainly due to competitive and pricing pressures, though Botox Cosmetic stays resilient.

Profitability and Margins Remain Healthy Despite R&D and Investment Headwinds

Adjusted diluted EPS came in at $10.00 for 2025, down slightly by 1.2% due to a $2.76 per share hit from acquired IPR&D and milestone expenses. The adjusted operating margin for Q4 stood at a robust 38.3%, and the adjusted gross margin at 83.6%, reflecting disciplined cost management amid ongoing investment—even as overall GAAP EPS decreased to $2.36. The adjusted tax rate in Q4 improved to 18.3%.

2026 Outlook: High Single-Digit Earnings Growth Anticipated

Management projects adjusted diluted EPS for 2026 in the range of $14.37 to $14.57, signaling high single-digit earnings expansion. This guidance excludes unforeseen expenses from future R&D asset acquisitions or milestones. The expectation is anchored in continued immunology and neuroscience growth, the launch and expansion of new indications, and a measured recovery in other segments.

Pipeline and Recent Milestones Position AbbVie for Long-Term Growth

Beyond financial results, AbbVie highlighted recent regulatory and R&D wins. Rinvoq is seeking an expanded FDA label for non-segmental vitiligo, potentially making it the first systemic therapy for the autoimmune condition. On the oncology front, the Epkinly combination was approved for relapsed/refractory follicular lymphoma, and further platform deals and acquisitions, such as the exclusive RemeGen partnership for RC148, bolster innovation potential. AbbVie also announced a $100 billion commitment to U.S. R&D and capital investments over the next decade, under a three-year agreement that provides certain tariff exemptions.

Key Takeaways for Investors: Diversification Mitigates Patent Loss Impact

AbbVie’s ability to outpace Humira’s patent expiration with new launches and category leadership in immunology and neuroscience underscores the company’s adaptability. The steady expansion of Skyrizi and Rinvoq, coupled with promising neuroscience and oncology assets, supplies a credible growth narrative through 2026 and beyond. Nevertheless, challenges in oncology and aesthetics remind investors to monitor portfolio execution and long-term pipeline productivity.

Full-Year and Q4 Financials: Quick Reference

Bottom Line: Attention Turns to 2026 Product Launches and Execution

While challenges remain in select franchises, AbbVie’s robust performance in 2025, its upgraded 2026 guidance, and proactive R&D agenda position the company as a leader in adapting to shifting pharmaceutical market dynamics. Investors will be watching closely as management seeks to translate pipeline progress into sustained commercial momentum in the year ahead.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI